DekaBank Deutsche Girozentrale Has $3.04 Million Stake in Progyny, Inc. (NASDAQ:PGNY)

DekaBank Deutsche Girozentrale boosted its position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 142.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 80,853 shares of the company's stock after purchasing an additional 47,500 shares during the period. DekaBank Deutsche Girozentrale owned 0.08% of Progyny worth $3,042,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. RiverPark Advisors LLC lifted its stake in shares of Progyny by 54.0% in the 4th quarter. RiverPark Advisors LLC now owns 1,067 shares of the company's stock valued at $40,000 after purchasing an additional 374 shares during the last quarter. Lazard Asset Management LLC bought a new stake in shares of Progyny during the 1st quarter worth about $62,000. Parkside Financial Bank & Trust bought a new stake in shares of Progyny during the 1st quarter worth about $70,000. Acadian Asset Management LLC acquired a new position in shares of Progyny during the 3rd quarter valued at about $53,000. Finally, International Assets Investment Management LLC bought a new position in shares of Progyny in the 3rd quarter valued at approximately $58,000. Institutional investors and hedge funds own 94.93% of the company's stock.

Insider Activity

In related news, Chairman David J. Schlanger sold 20,000 shares of the stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $38.50, for a total value of $770,000.00. Following the completion of the transaction, the chairman now owns 86,312 shares of the company's stock, valued at $3,323,012. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Chairman David J. Schlanger sold 20,000 shares of the business's stock in a transaction on Monday, February 5th. The stock was sold at an average price of $38.50, for a total value of $770,000.00. Following the sale, the chairman now owns 86,312 shares of the company's stock, valued at approximately $3,323,012. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Chairman David J. Schlanger sold 1,000 shares of the company's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $37.52, for a total value of $37,520.00. Following the completion of the sale, the chairman now owns 83,631 shares in the company, valued at $3,137,835.12. The disclosure for this sale can be found here. In the last three months, insiders have sold 120,515 shares of company stock worth $4,570,131. Corporate insiders own 14.30% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on PGNY. Leerink Partnrs restated an "outperform" rating on shares of Progyny in a research note on Monday, February 26th. KeyCorp dropped their price objective on Progyny from $45.00 to $43.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 28th. Barclays began coverage on Progyny in a research report on Wednesday, January 3rd. They set an "overweight" rating and a $48.00 price objective for the company. Cantor Fitzgerald restated an "overweight" rating and set a $48.00 target price on shares of Progyny in a research note on Wednesday, February 28th. Finally, Truist Financial dropped their price target on Progyny from $47.00 to $46.00 and set a "buy" rating on the stock in a research report on Wednesday, February 28th. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $48.30.

Progyny Stock Performance

Shares of NASDAQ:PGNY traded down $0.77 during trading on Friday, hitting $34.20. 368,436 shares of the stock were exchanged, compared to its average volume of 667,047. The company has a market capitalization of $3.30 billion, a price-to-earnings ratio of 55.16, a price-to-earnings-growth ratio of 1.44 and a beta of 1.48. Progyny, Inc. has a 1-year low of $29.44 and a 1-year high of $44.95. The company's fifty day simple moving average is $37.38 and its 200-day simple moving average is $35.71.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its earnings results on Tuesday, February 27th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.09 by $0.04. The firm had revenue of $269.94 million during the quarter, compared to analysts' expectations of $274.08 million. Progyny had a return on equity of 12.64% and a net margin of 5.70%. Progyny's quarterly revenue was up 26.0% compared to the same quarter last year. During the same period last year, the business earned $0.03 earnings per share. On average, research analysts forecast that Progyny, Inc. will post 0.7 earnings per share for the current fiscal year.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.